

Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

Berger JL, Smith A, Zorn KK, Sukumvanich P, Olawaiye AB, Kelley J, Krivak TC. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. *OncoTargets and Therapy*. 2014;7: 1409-1413.

This paper removed for legal reasons.